Company Of The Day: Pfizer

May 12th, 2022 by Trefis Team
+40.37%
Upside
40.16
Market
56.37
Trefis
PFE: Pfizer logo
PFE
Pfizer

What?

Pfizer (NYSE:PFE) plans to acquire Biohaven Pharmaceutical, a company that specializes in migraine treatments, in a deal valued at about $11.6 billion.

Why?

Relevant Articles
  1. Is Pfizer Stock Undervalued At $40?
  2. This Logistics Company Appears To Be A Better Pick Over Pfizer Stock
  3. What To Expect From Pfizer’s Q4?
  4. Is Pfizer Stock A Better Pick Over This Pharmaceuticals Bellwether?
  5. Company Of The Day: Pfizer
  6. Should You Buy Pfizer Stock Ahead of Its Q3 Results?

Pfizer is flush with cash from its Covid-19 vaccine and is looking at acquisitions to bolster revenue as vaccine sales peak off, with some of its top-selling drugs also set to go off patent.

So What?

We think Pfizer stock is undervalued. We value PFE at $63 per share, about 25% ahead of the current market price.

See Our Complete Analysis For Pfizer

What if you’re looking for a more balanced portfolio instead? Our high-quality portfolio and multi-strategy portfolio have beaten the market consistently since the end of 2016.

 Returns May 2022
MTD [1]		 2022
YTD [1]		 2017-22
Total [2]
 PFE Return 1% -16% 52%
 S&P 500 Return -5% -17% 76%
 Trefis Multi-Strategy Portfolio -9% -25% 196%

[1] Month-to-date and year-to-date as of 5/12/2022
[2] Cumulative total returns since the end of 2016

Invest with Trefis Market Beating Portfolios
See all Trefis Price Estimates